Vincent H J Van Der Velden

List of Publications by Year
in descending order

139 papers	5,957 citations	109321 35 h-index	79698 73 g-index
142 all docs	142 docs citations	142 times ranked	7554 citing authors

#	Article	IF	Citations
1	A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. Cell, 2014, 157, 369-381.	28.9	571
2	Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood, 2015, 125, 3996-4009.	1.4	410
3	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of Clinical Oncology, 2013, 31, 3889-3897.	1.6	392
4	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 2017, 129, 347-357.	1.4	323
5	Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. Journal of Clinical Oncology, 2016, 34, 2591-2601.	1.6	287
6	Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age-related changes and disease-induced shifts. Cytometry, 2004, 60B, 1-13.	1.8	266
7	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€“melphalanâ€“prednisone, with or without bortezomibâ€“lenalidomideâ€“dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology,the, 2020, 7, e456-e468.	4.6	244
8	Identification of distinct prognostic subgroups in low- and intermediate-1â€“risk myelodysplastic syndromes by flow cytometry. Blood, 2008, 111, 1067-1077.	1.4	205
9	CD33 expression and P-glycoproteinâ€“mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood, 2007, 109, 4168-4170.	1.4	176
10	Quality assessment program for <scp>E</scp>uro<scp>F</scp>low protocols: Summary results of fourâ€year (2010â€“2013) quality assurance rounds. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 145-156.	1.5	144
11	CD34+CD38â^' leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 2019, 33, 1102-1112.	7.2	130
12	Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia, 2002, 16, 1432-1436.	7.2	129
13	Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia, 2002, 16, 928-936.	7.2	120
14	T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia, 2002, 16, 1372-1380.	7.2	107
15	Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 2001, 15, 1485-1487.	7.2	91
16	MRD Detection in Acute Lymphoblastic Leukemia Patients Using Ig/TCR Gene Rearrangements as Targets for Real-Time Quantitative PCR. Methods in Molecular Biology, 2009, 538, 115-150.	0.9	83
17	CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry Part B - Clinical Cytometry, 2019, 96, 134-142.	1.5	82
18	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Advances, 2019, 3, 3393-3405.	5.2	81

#	Article	IF	Citations
19	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 2017, 102, 308-319.	3.5	74
20	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma, 2013, 54, 472-475.	1.3	66
21	Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. Oncotarget, 2017, 8, 4618-4628.	1.8	66
22	Leukemia surfaceome analysis reveals new disease-associated features. Blood, 2013, 121, e149-e159.	1.4	63
23	Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition. Journal of Clinical Oncology, 2011, 29, 1643-1649.	1.6	62
24	Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia, 2002, 16, 368-375.	7.2	58
25	Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica, 2017, 102, 320-326.	3.5	53
26	Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome. Haematologica, 2016, 101, 707-716.	3.5	51
27	B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood, 2014, 124, 412-419.	1.4	48
28	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood, 2021, 137, 1582-1590.	1.4	48
29	New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric Bâ€cell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 769-781.	2.5	44
30	Introduction to the diagnosis and classification of monocyticâ€lineage leukemias by flow cytometry. Cytometry Part B - Clinical Cytometry, 2017, 92, 218-227.	1.5	44
31	Fluorochrome choices for multi-color flow cytometry. Journal of Immunological Methods, 2019, 475, 112618.	1.4	43
32	Classification systems for acute and chronic leukaemias. Best Practice and Research in Clinical Haematology, 2003, 16, 561-582.	1.7	42
33	Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Journal of Clinical Oncology, 2021, 39, 652-662.	1.6	41
34	Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. Journal of Immunological Methods, 2019, 475, 112429.	1.4	40
35	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	3.5	38
36	Detailed immunophenotyping of Bâ€cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. British Journal of Haematology, 2017, 178, 257-266.	2.5	37

#	Article	IF	Citations
37	41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. , 2020, 8, e000845.		37
38	Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. Blood Advances, 2018, 2, 1532-1540.	5.2	36
39	EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. Journal of Immunological Methods, 2019, 475, 112662.	1.4	35
40	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer Journal, 2021, 11, 106.	6.2	31
41	Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: Report from the Dutch Working Party on Flow Cytometry in MDS. Leukemia Research, 2012, 36, 422-430.	0.8	29
42	Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples. Journal of Immunological Methods, 2019, 475, 112287.	1.4	29
43	Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. British Journal of Haematology, 2018, 183, 512-516.	2.5	27
44	Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection. Leukemia Research, 2019, 76, 98-104.	0.8	25
45	Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course. Frontiers in Immunology, 2021, 12, 684142.	4.8	25
46	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	1.6	25
47	Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. Journal of Immunological Methods, 2019, 475, 112680.	1.4	24
48	Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Practice and Research in Clinical Haematology, 2010, 23, 333-345.	1.7	23
49	Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?. Leukemia Research, 2019, 76, 39-47.	0.8	23
50	How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. Journal of Immunological Methods, 2019, 475, 112388.	1.4	23
51	Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica, 2006, 91, 679-82.	3.5	23
52	MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR. Methods in Molecular Biology, 2019, 1956, 199-228.	0.9	22
53	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia, 2022, 36, 1516-1524.	7.2	21
54	Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2006, 133, 382-388.	2.5	20

#	Article	IF	Citations
55	Decreased IL7RÎ± and TdT expression underlie the skewed immunoglobulin repertoire of human B-cell precursors from fetal origin. Scientific Reports, 2016, 6, 33924.	3.3	20
56	Lot-to-lot stability of antibody reagents for flow cytometry. Journal of Immunological Methods, 2019, 475, 112294.	1.4	20
57	<scp>CD</scp>38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. British Journal of Haematology, 2018, 180, 292-296.	2.5	18
58	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
59	Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones. Haematologica, 2017, 102, 1869-1877.	3.5	16
60	Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma. Acta Ophthalmologica, 2019, 97, 626-632.	1.1	16
61	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issuesâ€"Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
62	Severe COVID-19 Is Characterised by Perturbations in Plasma Amines Correlated with Immune Response Markers, and Linked to Inflammation and Oxidative Stress. Metabolites, 2022, 12, 618.	2.9	16
63	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. Modern Pathology, 2021, 34, 59-69.	5.5	15
64	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. Journal of Clinical Oncology, 2017, 35, 8011-8011.	1.6	15
65	Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers. Metabolites, 2022, 12, 619.	2.9	14
66	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology, 2022, 40, 3132-3150.	1.6	13
67	Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multiâ€centre setting. British Journal of Haematology, 2020, 190, 891-900.	2.5	11
68	Human Telomere Disease Due to Disruption of the CCAAT Box of the TERC Promoter. Blood, 2011, 118, 2405-2405.	1.4	11
69	Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2012, 120, 880-880.	1.4	11
70	Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study. Cancers, 2022, 14, 1583.	3.7	11
71	Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study. Lancet Haematology,the, 2021, 8, e700-e710.	4.6	10
72	A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study. Blood, 2020, 136, 8-9.	1.4	10

#	Article	IF	Citations
73	The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis. Leukemia, 2022, 36, 687-700.	7.2	10
74	Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2. Blood, 2021, 138, 82-82.	1.4	10
75	Minimal residual disease diagnostics in acute lymphoblastic leukaemia: impact of primer characteristics and size of junctional regions. British Journal of Haematology, 2014, 164, 451-453.	2.5	9
76	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. Modern Pathology, 2018, 31, 1318-1331.	5.5	9
77	Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. Cytometry Part B - Clinical Cytometry, 2018, 94, 928-934.	1.5	9
78	Flowcytometric evaluation of cerebrospinal fluid in childhood ALL identifies CNS involvement better then conventional cytomorphology. Leukemia, 2021, 35, 1773-1776.	7.2	9
79	Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.. Blood, 2008, 112, 3241-3241.	1.4	9
80	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. Haematologica, 2021, 106, 1496-1499.	3.5	9
81	Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. Blood Advances, 2021, , .	5.2	9
82	Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in <scp>T</scp>he <scp>N</scp>etherlands and <scp>B</scp>elgium: A way forward. Cytometry Part B - Clinical Cytometry, 2016, 90, 267-278.	1.5	8
83	Understanding the reconstitution of the Bâ€cell compartment in bone marrow and blood after treatment for Bâ€cell precursor acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 178, 267-278.	2.5	8
84	Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia. Leukemia, 2021, 35, 2403-2406.	7.2	8
85	VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma. American Journal of Clinical Pathology, 2022, 157, 494-497.	0.7	8
86	Flow cytometric minimal residual disease assessment in Bâ€cell precursor acute lymphoblastic leukaemia patients treated with CD19â€targeted therapies â€" a EuroFlow study. British Journal of Haematology, 2022, 197, 76-81.	2.5	8
87	PML-controlled responses in severe congenital neutropenia withELANE-misfolding mutations. Blood Advances, 2021, 5, 775-786.	5.2	7
88	A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study. Blood, 2019, 134, 2629-2629.	1.4	7
89	Machine Learning Based Analysis of Relations between Antigen Expression and Genetic Aberrations in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia. Journal of Clinical Medicine, 2022, 11, 2281.	2.4	7
90	No significant prognostic value of normal precursor <scp>B</scp>â€cell regeneration in paediatric acute myeloid leukaemia after induction treatment. British Journal of Haematology, 2013, 161, 861-864.	2.5	6

#	Article	IF	Citations
91	Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia. British Journal of Haematology, 2021, 193, 922-927.	2.5	6
92	B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. Cancers, 2021, 13, 1704.	3.7	6
93	Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. Haematologica, 2023, 108, 717-731.	3.5	6
94	Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease. British Journal of Haematology, 2001, 113, 1076-1089.	2.5	5
95	Effect of a Stable Angiotensinâ€(1â€“7) Analogue on Progenitor Cell Recruitment and Cardiovascular Function Post Myocardial Infarction. Journal of the American Heart Association, 2015, 4, .	3.7	5
96	Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Advances, 2022, 6, 1115-1125.	5.2	5
97	A series of case studies illustrating the role of flow cytometry in the diagnostic workâ€up of myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2022, , .	1.5	5
98	CD13/aminopeptidase N involvement in dendritic cell maturation. Leukemia, 2001, 15, 190-191.	7.2	4
99	Lossless Compression of Cytometric Data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 1108-1112.	1.5	4
100	Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development. Scientific Reports, 2020, 10, 13814.	3.3	4
101	Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all. British Journal of Haematology, 2021, 194, 888-892.	2.5	4
102	A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients. Blood, 2021, 138, 2558-2558.	1.4	4
103	Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world. Leukemia Research, 2019, 79, 69-74.	0.8	3
104	Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study. Leukemia, 2021, 35, 924-928.	7.2	3
105	Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.. Blood, 2006, 108, 2324-2324.	1.4	3
106	Efficacy and toxicity of highâ€risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, , e29387.	1.5	3
107	Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers, 2022, 14, 473.	3.7	3
108	Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patientsâ€"A EuroFlow Study. Cancers, 2022, 14, 2011.	3.7	3

#	Article	IF	Citations
109	Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome. Cancers, 2022, 14, 3088.	3.7	3
110	Usability of femoral head bone marrow to verify reference ranges for the assessment of myelodysplasia by flow cytometry. International Journal of Laboratory Hematology, 2018, 40, 726-733.	1.3	2
111	Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTC, the I-BFM and the Westhafen-Intercontinental-Group. Blood, 2016, 128, 985-985.	1.4	2
112	Standardization of WT1 mRNA Quantification for Minimal Residual Disease (MRD) Monitoring in Acute Leukemia Patients: A European LeukemiaNet Concerted Action.. Blood, 2005, 106, 3295-3295.	1.4	2
113	Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial , a Mantle Cell Lymphoma Network Study. Blood, 2021, 138, 40-40.	1.4	2
114	NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL. Blood, 2021, 138, 1314-1314.	1.4	2
115	Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies. Biomedicines, 2022, 10, 1229.	3.2	2
116	Longâ€term survival after significant treatment reduction in a patient with CBFâ€“AML. Pediatric Blood and Cancer, 2011, 56, 325-326.	1.5	1
117	Robust FCS Parsing: Exploring 211,359 Public Files. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 1180-1186.	1.5	1
118	Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Blood, 2020, 136, 41-42.	1.4	1
119	The Relevance of Stem Cell Load at Diagnosis for the Development of Relapse in Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 2584-2584.	1.4	1
120	NGS-Based Minimal Residual Disease (MRD) after Stem Cell Transplantation (SCT) Is More Specific for Relapse Prediction Than qPCR and Suggests the Possibility of False-Positive qPCR Results. Blood, 2016, 128, 3494-3494.	1.4	1
121	Detection of Genomic Lesions in Childhood Precursor-B Cell ALL in Diagnosis and Relapse Samples Using High Resolution Genomic Profiling.. Blood, 2007, 110, 995-995.	1.4	1
122	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. Blood, 2016, 128, 2072-2072.	1.4	1
123	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission â€“ results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 2022, 22, 147.	2.6	1
124	Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation. Haematologica, 2006, 91, 291A.	3.5	1
125	Immunoglobulin Light Chain Gene Rearrangements in Childhood Precursor-B-ALL: Immunobiological Characteristics and Applicability for the Detection of Minimal Residual Disease.. Blood, 2005, 106, 1442-1442.	1.4	0
126	Comparative Analysis of Gene Expression Profiles between Diagnosis and Relapse of Childhood Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2809-2809.	1.4	0

#	Article	IF	Citations
127	Late Relapses of Childhood T-ALL Are Frequently Second T-ALL.. Blood, 2007, 110, 1435-1435.	1.4	0
128	Proteomic Exploration of the Cell Surface Landscape Reveals New Leukemia Associated Features.. Blood, 2012, 120, 2506-2506.	1.4	0
129	Telomere Length and Telomerase Complex Mutations in Pediatric Acute Myeloid Leukemia. Blood, 2012, 120, 1482-1482.	1.4	0
130	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Mul̂nster AML Study Group.. Blood, 2012, 120, 2516-2516.	1.4	0
131	Immunophenotyping Versus Morphological Evaluation Of Fresh and Stabilized Cerebrospinal Fluid As Diagnostic Tool For CNS Involvement In Childhood Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4950-4950.	1.4	0
132	Recovery of the Normal B-Cell Compartment in Children Treated for B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3792-3792.	1.4	0
133	Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage. Blood, 2014, 124, 1067-1067.	1.4	0
134	Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood. Blood, 2014, 124, 1916-1916.	1.4	0
135	The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC). Blood, 2015, 126, 1657-1657.	1.4	0
136	Euroflow-Based Immunophenotypic Characterization of CD34+ Cell Compartment in Juvenile Myelomonocytic Leukemia (JMML): A New Tool for Differential Diagnosis. Blood, 2016, 128, 3127-3127.	1.4	0
137	Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation. Blood, 2019, 134, 2687-2687.	1.4	0
138	Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study. Blood, 2019, 134, 827-827.	1.4	0
139	Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Blood, 2021, 138, 2383-2383.	1.4	0